Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.
Abstract: The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is from about 1:0.75 to about 1:20; wherein, composition comprising melphalan, at a concentration of about 50 mg/ml to about 150 mg/ml; wherein, when the composition is diluted to produce melphalan at a concentration of about 0.1 to about 3 mg/ml, is physically and chemically stable up to about 4 hours.
Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.